It has been indicated recently that miR-140-3p can enhance the antitumor effect of sorafenib via targeting pregnane X recptor (PXR) resulting down-regulation of drug-resistance related genes in HCC cells (Li et al., 2018). The gene discussed is NR1I2; the disease is hepatocellular carcinoma.